Pelacarsen Failed — What Ionis Has Left

The drug worked exactly as designed — it just didn't matter to patients.

Pelacarsen, the Novartis-Ionis drug built to lower lipoprotein(a), reduced the inherited cholesterol particle by roughly 67 percent in its Phase 3 trial. That was the easy part. The hard part — proving that lowering Lp(a) translates into fewer heart attacks, strokes, and cardiovascular deaths — did not happen. The Lp(a)HORIZON trial of 8,323 patients with established cardiovascular disease missed its primary endpoint on Friday.

Ionis shares fell 6 percent in after-hours trading. The reaction was muted compared to the 23 percent plunge Ionis suffered in July when its other late-stage candidate, Wainua, failed in an amyloid cardiomyopathy trial. Two blockbuster pipeline programs down within seven weeks. The stock has lost nearly a third from its 52-week high of $86.74 and sits near $58, down 27 percent year-to-date.

The market's restrained reaction to pelacarsen is not indifference. It's arithmetic. The question for investors is whether Ionis still has enough left standing after two consecutive trial failures.

The Lp(a) hypothesis — and why it just got harder

Lp(a) is an inherited, genetically determined risk factor for cardiovascular disease that affects roughly 20 percent of the global population. For decades, physicians could measure it but do nothing about it. No approved therapy existed. The idea was elegant: if human genetics link high Lp(a) to heart attacks, then lowering it with a drug should prevent them.

Pelacarsen was the first drug to test that idea head-on in a cardiovascular outcomes trial. The mechanism — an antisense oligonucleotide that blocks Lp(a) production in the liver — worked beautifully. Earlier studies showed reductions of up to 67 percent at 80-milligram doses. The molecule could lower the biomarker. It couldn't lower the risk.

That distinction is critical. The lipid-lowering world has been burned before. Drugs that raised HDL looked promising on paper but failed in outcomes trials. Lowering a number is not the same as improving a patient's fate. Ionis CEO Brett Monia called the result "disappointing" — understatement aside, the biomarker-to-outcome disconnect is now a real problem for every company in the Lp(a) race.

The competitive landscape hasn't gotten easier because of this result, even if the pelacarsen-specific door has closed. Amgen's olpasiran has an outcomes trial expected in early 2027. Eli Lilly is testing lepodisiran with data projected for 2029. Different designs, different populations — Amgen is testing primary prevention (first heart attacks) while pelacarsen tested secondary prevention (patients with existing disease). So the broader Lp(a) hypothesis isn't dead. But the first major test failed, and that casts a shadow.

What's left of Ionis

Here's where the factor work starts. A failed pipeline asset is a story. What matters is whether the remaining economics can support the $9.7 billion market cap and where Ionis sits relative to its biotech peers on valuation, growth, and cash-flow trajectory.

Two approved drugs are generating real revenue now. Tryngolza (olezarsen), launched in 2024 for a rare triglyceride disorder, brought in $108 million in 2025 and is guided for $100-110 million in 2026. DAWNZERA (donidalorsen), approved in 2024 for hereditary angioedema, is on track for $110-120 million this year. Management raised full-year 2026 revenue guidance to $875-900 million and lifted the peak sales view for olezarsen to above $3 billion as new indications are added.

Two more approvals loom within weeks. Zilganersen for Alexander disease received FDA approval on September 3rd — the first-ever disease-modifying treatment for this rare pediatric neurological condition. Bepirovirsen for chronic hepatitis B has a PDUFA date of October 26th and is under review in the U.S., EU, Japan, and China. Both are near-term commercial events, not speculative pipeline bets.

The cash position provides runway through the transition. Ionis held $2.1 billion in cash and short-term investments as of June 30. Operating losses narrowed from $102 million in Q2 (GAAP) to $57 million on a non-GAAP basis. The company targets cash-flow breakeven in 2028 — roughly 13 months away. That timeline assumed no catastrophic setbacks, but losing pelacarsen and Wainua from the long-term outlook is a revenue gap the market hasn't fully resolved.

Valuation context — does the price reflect the damage?

Ionis trades at a negative P/E — the company is not yet profitable on a GAAP basis. The price-to-sales ratio sits at 11x on trailing revenue, which sounds rich until you remember that revenue jumped 49 percent in 2025 and is guided to grow again in 2026. Two new product launches by late October could change that denominator materially.

Compared to biotech peers, Ionis sits in an unusual place. It's no longer a pure clinical-stage company burning cash for a binary readout. It's not yet a profitable, cash-flowing business. It lives in the gap between the two. Biomarin trades at 3.8x sales with positive earnings. Regeneron trades at 5.5x sales with a 19.7x P/E and a dividend. Moderna, still negative on earnings, trades at 26x sales but carries a much larger market cap ($58 billion) and an mRNA platform that investors are pricing differently. Ionis at 11x sales with $9.7 billion market cap is not cheap. It's priced for the execution that follows the approvals.

That execution risk is the live question. Pelacarsen's failure removes one potential revenue pillar. Wainua's July loss removed another. Together they were part of a longer-term growth story that included Novartis' commercialization muscle. Without them, the market cap is supported by Tryngolza's expanding indications, DAWNZERA's early trajectory, Zilganersen's imminent launch, Bepirovirsen's global review, and a deep pipeline of 10+ programs. The risk is that all of those near-term catalysts deliver and the stock still can't grow out of its multiple because the large-cardio franchise door closed.

The portfolio question

Ionis has shifted from a story stock to a portfolio decision. Before July, the pelacarsen and Wainua programs were option value — large payoffs conditional on trial success. Those options have been knocked out. What's left is a company with two approved products, two more launching within weeks, $2.1 billion in cash, and a 2028 breakeven target.

For a holder, the question is whether to treat the recent drawdown as a forced exit from a deteriorating portfolio role or as a repricing toward the underlying business. A stock down 27 percent year-to-date after two sequential failures doesn't automatically deserve conviction. But it also doesn't deserve dismissal when the near-term catalyst calendar — Zilganersen launch and Bepirovirsen approval in October — is compressed into a six-week window.

For a watcher, the math is simpler. The stock is below its 50-day moving average ($61) and its 200-day moving average ($73), with an RSI near 45 — in the middle, not oversold, not overbought. The technicals suggest the selling is pausing, not accelerating. The question is whether the October approvals are enough to reprice the stock toward a profile that justifies its current multiple.

Two failures in seven weeks is not a pattern that commands confidence. But Ionis is no longer the company that was priced for those two failures to succeed. The stock has adjusted. The remaining portfolio of approved drugs, imminent launches, and cash runway is what the market cap must now justify. Whether it can is the question the October approvals will begin to answer.